tiprankstipranks
Trending News
More News >
Rapid Micro Biosystems (RPID)
NASDAQ:RPID
US Market
Advertisement

Rapid Micro Biosystems (RPID) AI Stock Analysis

Compare
91 Followers

Top Page

RPID

Rapid Micro Biosystems

(NASDAQ:RPID)

Select Model
Select Model
Select Model
Neutral 45 (OpenAI - 4o)
Rating:45Neutral
Price Target:
$3.00
▲(2.39% Upside)
The overall stock score reflects significant financial challenges, including persistent losses and negative cash flows, which weigh heavily on the company's outlook. Technical indicators suggest mixed momentum, while valuation metrics highlight a challenging environment due to negative earnings. The earnings call provided some positive strategic developments, but ongoing market uncertainties and product margin challenges remain significant concerns.
Positive Factors
Revenue Growth
The consistent revenue growth, particularly in consumables and services, indicates strong demand and a robust business model, supporting long-term sustainability.
New Term Loan Facility
The new loan facility enhances financial flexibility, enabling strategic investments and supporting long-term growth objectives.
MilliporeSigma Partnership
The partnership with MilliporeSigma could lead to cost reductions and expanded market opportunities, strengthening competitive positioning.
Negative Factors
Product Margin Challenges
Negative product margins indicate ongoing cost issues, which could hinder profitability and require strategic adjustments to improve.
Operating Loss
Continued operating losses highlight challenges in achieving profitability, necessitating operational improvements to ensure long-term viability.
Uncertainty in System Placements
Uncertainty in system placements due to global trade dynamics may impact revenue growth, requiring strategic focus on market expansion.

Rapid Micro Biosystems (RPID) vs. SPDR S&P 500 ETF (SPY)

Rapid Micro Biosystems Business Overview & Revenue Model

Company DescriptionRapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in North America, Europe, and Asia. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and comprehensive customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides installation and verification, technical training, and support services. Its solutions are used in environmental monitoring, water testing, bioburden, and sterility release testing applications. The company was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. Rapid Micro Biosystems, Inc. was incorporated in 2006 and is headquartered in Lowell, Massachusetts.
How the Company Makes MoneyRapid Micro Biosystems generates revenue through the sale of its Growth Direct System and related consumables, including proprietary growth media and software. The company operates on a recurring revenue model, benefiting from ongoing sales of consumables and maintenance services. Additionally, RPID partners with various pharmaceutical and biotech companies to provide customized solutions, which can lead to lucrative long-term contracts. The expansion of its customer base and the growing demand for rapid microbial testing in regulated industries contribute significantly to its earnings.

Rapid Micro Biosystems Earnings Call Summary

Earnings Call Date:Aug 12, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Nov 06, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted significant revenue growth and strategic advancements, including a new loan facility and partnership progress. However, challenges remain with product margins and ongoing market uncertainties affecting system placements.
Q2-2025 Updates
Positive Updates
Revenue Growth
Total revenue increased 10% year-over-year to $7.3 million, with mid- to high-teens growth in both consumables and service. Recurring revenue increased 15%.
New Term Loan Facility
Announced a new $45 million, 5-year term loan facility with Trinity Capital, which supports long-term strategy and reinforces the ability to achieve positive cash flow.
Gross Margin Improvement
Gross margins improved by 7 percentage points from the prior year, marking the fourth consecutive quarter of positive gross margins.
MilliporeSigma Partnership
Meaningful progress in the commercial partnership with MilliporeSigma, including joint development of commercial opportunities and initiatives to lower product costs.
Negative Updates
Product Margin Challenges
Product margins were negative 11% in the quarter, slightly down compared to Q2 2024 due to fewer system placements and revenue mix.
Operating Loss
Net loss was $11.9 million, compared to a net loss of $12.6 million in Q2 2024. Net loss per share was $0.27.
Uncertainty in System Placements
Guidance towards the low end of the previous system placements range due to ongoing uncertainty in trade dynamics and global market conditions.
Company Guidance
During the Rapid Micro Biosystems Second Quarter 2025 Earnings Conference Call, the company provided guidance indicating a positive outlook for the remainder of the year despite some uncertainties. Total second-quarter revenue increased by 10% year-over-year to $7.3 million, with consumables and service revenue experiencing mid- to high-teens growth. The company reaffirmed its full-year revenue guidance of at least $32 million, although it anticipates finishing towards the low end of its previous guidance range of 21 to 25 system placements due to ongoing global trade dynamics affecting customer purchase decisions. Gross margins improved by 7 percentage points from the prior year to 4%, with expectations of further improvements in the fourth quarter. Operating expenses decreased by 6% year-over-year to $12.4 million, and the net loss per share improved to $0.27 from $0.29 in the previous year. The company also highlighted a new $45 million term loan facility to support long-term strategy execution, with the first $20 million tranche already drawn.

Rapid Micro Biosystems Financial Statement Overview

Summary
Rapid Micro Biosystems faces significant financial challenges, with persistent losses and negative cash flows. While revenue growth is present, profitability and cash generation remain critical issues. The balance sheet shows low leverage, which is a positive, but the company needs to address its operational inefficiencies to improve financial health.
Income Statement
25
Negative
Rapid Micro Biosystems shows a modest revenue growth rate of 2.17% TTM, but the company struggles with profitability as evidenced by negative margins across the board. The gross profit margin is low at 18.91%, and the net profit margin is significantly negative at -145.63%, indicating substantial losses. The EBIT and EBITDA margins are also deeply negative, reflecting operational challenges.
Balance Sheet
40
Negative
The company maintains a low debt-to-equity ratio of 0.10 TTM, suggesting conservative leverage. However, the return on equity is negative at -63.07%, indicating inefficiencies in generating returns from equity. The equity ratio stands at 72.15%, showing a strong equity base relative to total assets, which is a positive aspect.
Cash Flow
30
Negative
The cash flow situation is concerning, with negative operating and free cash flows. The free cash flow growth rate is negative at -132% TTM, highlighting deteriorating cash generation. The operating cash flow to net income ratio is -2.27, indicating cash flow challenges relative to net losses. However, the free cash flow to net income ratio is slightly positive at 1.03, suggesting some alignment between cash flow and accounting losses.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue30.29M28.05M22.52M17.13M23.23M16.08M
Gross Profit5.73M-109.00K-5.49M-8.54M-7.74M-8.07M
EBITDA-43.92M-46.56M-53.46M-60.38M-45.80M-32.00M
Net Income-44.11M-46.89M-52.47M-60.81M-73.52M-37.08M
Balance Sheet
Total Assets75.59M98.17M143.45M190.65M241.17M70.00M
Cash, Cash Equivalents and Short-Term Investments31.25M50.73M92.05M108.65M193.50M45.08M
Total Debt5.58M6.17M7.35M7.97M400.00K24.81M
Total Liabilities21.04M22.82M25.46M26.48M20.19M45.18M
Stockholders Equity54.55M75.35M117.99M164.17M220.98M24.82M
Cash Flow
Free Cash Flow-38.28M-45.52M-46.93M-65.29M-58.18M-31.69M
Operating Cash Flow-37.27M-44.15M-45.08M-58.55M-54.96M-31.00M
Investing Cash Flow18.35M36.66M42.15M-93.47M-13.29M-15.67M
Financing Cash Flow136.00K203.00K149.00K693.00K216.75M64.23M

Rapid Micro Biosystems Technical Analysis

Technical Analysis Sentiment
Negative
Last Price2.93
Price Trends
50DMA
3.01
Negative
100DMA
3.26
Negative
200DMA
2.84
Positive
Market Momentum
MACD
-0.02
Positive
RSI
42.20
Neutral
STOCH
29.47
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RPID, the sentiment is Negative. The current price of 2.93 is below the 20-day moving average (MA) of 3.34, below the 50-day MA of 3.01, and above the 200-day MA of 2.84, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 42.20 is Neutral, neither overbought nor oversold. The STOCH value of 29.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RPID.

Rapid Micro Biosystems Risk Analysis

Rapid Micro Biosystems disclosed 70 risk factors in its most recent earnings report. Rapid Micro Biosystems reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Rapid Micro Biosystems Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
56
Neutral
$245.60M-57.10%-3.89%9.68%
53
Neutral
$102.16M-77.26%-9.59%8.78%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
51
Neutral
$171.53M-463.56%14.74%14.63%
45
Neutral
$138.82M-59.15%22.57%14.11%
45
Neutral
$68.05M-66.88%18.24%4.81%
42
Neutral
$146.56M-350.22%29.34%-283.53%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
RPID
Rapid Micro Biosystems
2.93
2.01
218.48%
LUNG
Pulmonx
1.61
-4.52
-73.74%
LNSR
LENSAR
12.26
6.66
118.93%
HYPR
Hyperfine
1.28
0.30
30.61%
SGHT
Sight Sciences
5.16
-0.25
-4.62%
LUCD
Lucid Diagnostics
1.21
0.36
42.35%

Rapid Micro Biosystems Corporate Events

Private Placements and FinancingFinancial Disclosures
Rapid Micro Biosystems Secures $45M Loan for Growth
Positive
Aug 12, 2025

On August 8, 2025, Rapid Micro Biosystems entered into a Loan and Security Agreement with Trinity Capital Inc., securing a $45 million term loan facility to bolster its financial position and support long-term growth. The company reported a 10% increase in total revenue for the second quarter of 2025 compared to the previous year, driven by strong performance in service and product revenue, and reaffirmed its full-year revenue guidance of at least $32 million.

Executive/Board ChangesBusiness Operations and Strategy
Rapid Micro Biosystems CEO Diagnosed with Lymphoma
Neutral
Jun 17, 2025

On June 17, 2025, Robert Spignesi, CEO of Rapid Micro Biosystems, announced his diagnosis with a treatable form of Lymphoma. Despite the diagnosis and ongoing treatment, Spignesi plans to continue leading the company with limited in-person presence, expressing confidence in the company’s ability to maintain its performance and thanking the team for their support.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 18, 2025